Thomas Reinke

Medication safety can be seen as a global concern requiring close collaboration

Thomas Reinke

Globalization of drug development and drug marketing has spawned a movement, though small, toward international drug regulation. In a Dec. 15, 2010 interview with the Wall Street Journal, Thomas Lonngren, outgoing head of the European Medicines Agency, which approves drugs in Europe, said the FDA and EMA are working together on drug approvals.

A day later came this headline on an FDA news release: “FDA begins process to remove breast cancer indication from Avastin label.”

Simultaneously, a news release from London read, “European Medicines Agency completes its review of Avastin used in breast cancer.”

First there was Avandia

The two agencies took coordinated action to curtail the use of Avastin (bevacizumab). The EMA’s action was definitive; it eliminated authorization for one select combination therapy while allowing continued use in another combination therapy.

The FDA’s announcement signaled its intention to totally remove approval for the breast cancer indication. However, one final step remained open: the option for an appeal by Roche, Avastin’s manufacturer. Roche filed that appeal and the drug remains available. The FDA may grant or deny that hearing.

Avastin is used in combination with other agents to treat colon, rectum, lung, kidney, or breast cancer. The actions of the two agencies do not affect its use for the other indications.

This was the second time the two agencies have worked together. In September 2010 they came out against GlaxoSmithKline’s Avandia, a diabetes drug with heart attack risks. The actions on Avandia were the mirror image of the current situation. It was banned in Europe and only restricted in this country. The result sealed Avandia’s fate, although sales had fallen dramatically before the announcements: Roche now projects minimal sales.

Lonngren said the timing of the Avandia announcements was deliberate, and he was quoted as saying this was an “example of how enforcement will be done in the future.”

The actions so far have focused on drug safety, not new drug approvals. Global distribution of medications means that when safety concerns arise in one country, there are worldwide implications. The need for cooperation is clear. Furthermore, clinical trial data are easily available worldwide, and regulatory agencies certainly should consider all credible information that is available to them.

Cooperation may give leverage to evidence-based drug decisions, because concern may arise when one regulatory agency takes action but another doesn’t. A decision by one agency can be criticized by citing the other agency’s inaction. The credibility and responsiveness of one agency may also come into question.

Cooperation may also benefit the regulators in emotionally charged situations. The FDA’s Avastin decision produced a significant backlash, including a sensationalistic post, “The Death Panel’s First Murder,” on the American Spectator’s blog. It speculated on the possibility of more breast cancer deaths and called the FDA ruling a bureaucratic, elitist, and authoritarian command.

Head vs. heart

Emotional and political decisions can override science, such as the November 2009 recommendation of the U.S. Preventive Services Task Force to change the recommendation for mammograms to age 50 from age 40. It was overridden in the Affordable Care Act with mandatory coverage of mammograms beginning at age 40.

The FDA originally approved Avastin under its accelerated approval program, but later studies showed risks to outweigh benefits.

Contact the author at TReinke@ManagedCareMag.com.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.